Phaarmasia

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE486I01016
  • NSEID:
  • BSEID: 523620
INR
117.00
-2.96 (-2.47%)
BSENSE

Feb 12

BSE+NSE Vol: 1.23 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Phaarmasia
Concord Drugs
Sunil Healthcare
Samrat Pharma
Bharat Immunolog
Guj. Inject(Ker)
Kabra Drugs
Amwill Health
Shelter Pharma
Accretion Pha.
Zenith Drugs

Why is Phaarmasia Ltd ?

1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.45%
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.99
2
With a growth in Net Profit of 835.06%, the company declared Very Positive results in Dec 25
  • The company has declared positive results for the last 2 consecutive quarters
  • NET SALES(Latest six months) Higher at Rs 32.60 cr
  • PAT(Latest six months) Higher at Rs 2.48 cr
  • ROCE(HY) Highest at 7.91%
3
With ROE of 20.7, it has a Attractive valuation with a 7.6 Price to Book Value
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 172.29%, its profits have risen by 281% ; the PEG ratio of the company is 0.1
4
Majority shareholders : Promoters
5
Market Beating performance in long term as well as near term
  • Along with generating 172.29% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Phaarmasia should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Phaarmasia for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Phaarmasia
176.66%
3.03
56.90%
Sensex
10.18%
0.88
11.44%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
17.53%
EBIT Growth (5y)
21.34%
EBIT to Interest (avg)
-0.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
2.35
Tax Ratio
17.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
-10.15%
ROE (avg)
1.45%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
37
Industry P/E
33
Price to Book Value
7.63
EV to EBIT
49.08
EV to EBITDA
42.65
EV to Capital Employed
7.90
EV to Sales
1.81
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
20.69%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company
NET SALES(Latest six months)

Higher at Rs 32.60 cr

PAT(Latest six months)

Higher at Rs 2.48 cr

ROCE(HY)

Highest at 7.91%

EPS(Q)

Highest at Rs 23.82

-2What is not working for the Company
DEBTORS TURNOVER RATIO(HY)

Lowest at 2.44 times

Loading Valuation Snapshot...

Here's what is working for Phaarmasia

Net Sales - Latest six months
At Rs 32.60 cr has Grown at 206.10%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
At Rs 2.48 cr has Grown at 285.22%
Year on Year (YoY)
MOJO Watch
PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months
Higher at Rs 32.60 cr
than preceding 12 month period ended Dec 2025 of Rs 22.95 cr
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
Higher at Rs 2.48 cr
than preceding 12 month period ended Dec 2025 of Rs -1.60 cr
MOJO Watch
In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 23.82
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Phaarmasia

Debtors Turnover Ratio- Half Yearly
Lowest at 2.44 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio